GLP-1 Program

Overview

What It Is

Our GLP-1 program combines compounded Semaglutide or Tirzepatide with clinical oversight, nutrition guidance, and body composition tracking. Weight loss the way it should be done — safely, sustainably, and with a medical team beside you.

Meaningful, sustained weight loss
Appetite regulation and reduced cravings
Improved metabolic markers and insulin response
Personalized dose titration by our physicians

The Mechanism

The Mechanism, In Plain Clinical Terms

Semaglutide is a GLP-1 receptor agonist; Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both mimic incretin hormones — slowing gastric emptying, enhancing glucose-dependent insulin secretion, and signaling satiety through hypothalamic pathways. The result is reduced appetite, improved glycemic control, and sustained weight loss.

Evidence

What The Peer-Reviewed Literature Shows

Semaglutide 2.4 mg for Weight Management (STEP 1 Trial)

Wilding et al., New England Journal of Medicine, 2021

68 weeks of weekly Semaglutide produced a mean weight loss of 14.9% vs. 2.4% for placebo in adults with obesity — a landmark result establishing modern GLP-1 weight care.

Tirzepatide Once Weekly for Obesity (SURMOUNT-1)

Jastreboff et al., New England Journal of Medicine, 2022

At 72 weeks, Tirzepatide 15 mg produced a mean weight reduction of 20.9% — the largest weight loss reported for a pharmacologic monotherapy.

Semaglutide and Cardiovascular Outcomes in Obesity (SELECT)

Lincoff et al., New England Journal of Medicine, 2023

Semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in patients with overweight/obesity and pre-existing cardiovascular disease.

Protocol

Prescribed Responsibly. Monitored Throughout.

Includes initial consultation, medical clearance, monthly medication, and ongoing check-ins with our clinical team. Compounded and dispensed through our licensed partner pharmacy.

Ideal For

BMI qualifying for medical weight management
Plateau on diet and exercise alone
Metabolic syndrome or insulin resistance
Long-term body composition goals

Safety

Prescription-only, requires medical clearance and ongoing monitoring.
Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2.
Not for use in pregnancy or breastfeeding.
Most common effects: nausea, constipation, and early satiety — typically transient and dose-related.
Rare risks include pancreatitis and gallbladder disease; report severe abdominal pain immediately.

Questions

Your Questions, Answered

Semaglutide or Tirzepatide — which is right for me?

Your physician will recommend based on your labs, medical history, weight-loss goals, and tolerability. Both are effective; Tirzepatide typically produces greater average weight loss.

How much weight will I lose?

Clinical trials show 15–20% mean body weight reduction over 12+ months. Individual results depend on dose response, nutrition, activity, and sleep.

What happens when I stop?

GLP-1s work while you take them. We build a transition plan — including strength training, protein-forward nutrition, and, when appropriate, a maintenance dose — to protect your results.

How is muscle mass protected?

We track body composition, prescribe adequate protein (1.6–2.2 g/kg), and integrate resistance training. In select cases we layer peptides to preserve lean mass.

The Apothecary

Explore More Programs

Peptide

Begin

Prescribed With Care

Every protocol is prescribed and monitored by our clinical team.

Book Now View Treatments